UK Pharma Claims Breakthrough On COVID Treatment

CNBC reports:

British pharmaceutical company Synairgen has claimed that its new respiratory coronavirus treatment has reduced the number of hospitalized Covid-19 patients needing intensive care in a clinical trial.

The company said its nebulizer treatment produced a 79% lower risk of patients developing severe disease than those given a placebo in initial trials.

Patients that received the treatment “were more than twice as likely to recover (defined as ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’) over the course of the treatment period compared to those receiving placebo,” Synairgen claimed.